Advertisement
Research Article| Volume 159, ISSUE 1, P115-118, November 2011

Download started.

Ok

Attitudes of Spanish women toward premenstrual symptoms, premenstrual syndrome and premenstrual dysphoric disorder: results of a nationwide survey

      Abstract

      Objective

      To assess the attitudes of women with premenstrual symptoms in relation to their perception of complaints and request for medical advice.

      Study design

      Cross-sectional study of a representative cohort of 2018 Spanish women aged 15–49 years. Participants were personally interviewed at home and completed the premenstrual symptoms screening tool.

      Results

      A total of 1554 women (73.7%) complained of some of the premenstrual symptoms during the last 12 menstrual cycles. The prevalence of moderate or severe premenstrual syndrome (PMS) was 8.9% and the prevalence of premenstrual dysphoric disorder (PMDD) 1.1%. Only 291 (18.7%) women had sought medical advice. The main reason given by 90.6% of symptomatic women for not seeking medical consultation was to consider that symptoms were normal. A total of 175 (60.1%) women received pharmacological treatment (hormonal contraceptives in 95% followed by analgesics in 50% and anti-inflammatory agents in 44%), 20% were not treated because physicians considered that symptoms were not important and would disappear spontaneously, and 12% received only advice to change life style.

      Conclusion

      Women suffering from PMS or PMDD do not usually seek medical advice and among those seeking medical care, in many cases, an adequate response to their demands is not obtained.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Mortola J.F.
        • Girton L.
        • Beck L.
        • Yen S.S.
        Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences.
        Obstet Gynecol. 1990; 76: 302-307
      1. American College of Obstetricians and Gynecologists. Premenstrual syndrome. Washington, DC: American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 15; 2000.

        • Pearlstein T.
        Prevalence, impact on morbidity and disease burden.
        in: O’Brien S. Rapkin A.J. Schmidt P.J. The premenstrual syndromes: PMS and PMDD. Informa UK, Ltd., London2007: 37-47
        • Freeman E.W.
        Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder.
        Pharmacoeconomics. 2005; 23: 433-444
        • Chawla A.
        • Swindle R.
        • Long S.
        • Kennedy S.
        • Sternfeld B.
        Premenstrual dysphoric disorder: is there an economic burden of illness?.
        Med Care. 2002; 40: 1101-1112
        • Halbreich U.
        • Borenstein J.
        • Pearlstein T.
        • Kahn L.S.
        The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).
        Psychoneuroendocrinology. 2003; 28: 1-23
        • Dueñas J.L.
        • Lete I.
        • Bermejo R.
        • et al.
        Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a representative cohort of Spanish women of fertile age.
        Eur J Obstet Gynecol Reprod Biol. 2011; 156: 72-77
        • Steiner M.
        • Macdougall M.
        • Brown E.
        The premenstrual symptoms screening tool (PSST) for clinicians.
        Arch Women's Ment Health. 2003; 6: 203-209
        • Rivera-Tovar A.D.
        • Frank E.
        Late luteal phase dysphoric disorder in young women.
        Am J Psychiatry. 1990; 147: 1634-1636
        • Cohen L.S.
        • Soares C.N.
        • Otto M.W.
        • Sweeney B.H.
        • Liberman R.F.
        • Harlow B.L.
        Prevalence and predictors of premenstrual dysphoric disorder (PMDD) in older premenopausal women. The Harvard Study of Moods and Cycles.
        J Affect Disord. 2002; 70: 125-132
        • Corney R.H.
        • Stanton R.
        A survey of 658 women who report symptoms of premenstrual syndrome.
        J Psychosom Res. 1991; 35: 471-482
        • Campbell E.M.
        • Peterkin D.
        • O’Grady K.
        • Sanson-Fisher R.
        Premenstrual symptoms in general practice patients. Prevalence and treatment.
        J Reprod Med. 1997; 42: 637-646
        • Weisz G.
        • Knaapen L.
        Diagnosing and treating premenstrual syndrome in five western nations.
        Soc Sci Med. 2009; 68: 1498-1505
        • Yücel B.
        • Polat A.
        Attitudes toward menstruation in premenstrual dysphoric disorder: a preliminary report in an urban Turkish population.
        J Psychosom Obstet Gynaecol. 2003; 24: 231-237
        • Adewuya A.O.
        • Loto O.M.
        • Adewumi T.A.
        Premenstrual dysphoric disorder amongst Nigerian university students: prevalence, comorbid conditions, and correlates.
        Arch Women's Ment Health. 2008; 11: 13-18
        • Kraemer G.R.
        • Kraemer R.R.
        Premenstrual syndrome: diagnosis and treatment experiences.
        J Women's Health. 1998; 7: 893-907
        • Bäckström T.
        • Andreen L.
        • Birzniece V.
        • et al.
        The role of hormones and hormonal treatments in premenstrual syndrome.
        CND Drugs. 2003; 17: 325-342
        • Joffe H.
        • Cohen L.S.
        • Harlow B.L.
        Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration.
        Am J Obstet Gynecol. 2003; 189: 1523-1530
        • Ross C.
        • Coleman G.
        • Stojanovska C.
        Factor structure of the modified Moos Menstrual Distress Questionnaire: assessment of prospectively reported follicular, menstrual and premenstrual symptomatology.
        J Psychosom Obstet Gynaecol. 2003; 24: 163-174
        • Singh B.B.
        • Berman B.M.
        • Simpson R.L.
        • Annechild A.
        Incidence of premenstrual syndrome and remedy usage: a national probability sample study.
        Altern Ther Health Med. 1998; 4: 75-79
        • Schulman L.P.
        Gynecological management of premenstrual symptoms.
        Curr Pain Headache Rep. 2010; 14: 367-375
        • Freeman E.W.
        Therapeutic management of premenstrual syndrome.
        Expert Opin Pharmacother. 2010; 11: 2879-2889
        • Whelan A.M.
        • Jurgens T.M.
        • Naylor H.
        Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review.
        Can J Clin Pharmacol. 2009; 16: e407-e429
        • Brown J.
        • O’Brien P.M.S.
        • Marjoribanks J.
        • Wyatt K.
        Selective serotonin reuptake inhibitors for premenstrual syndrome.
        Cochrane Database Syst Rev. 2009; ([Art. No.: CD001396])https://doi.org/10.1002/14651858.CD001396.pub2
        • Rapkin A.
        A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder.
        Psychoneuroendocrinology. 2003; 28: 39-53
        • Lopez L.M.
        • Kaptein A.A.
        • Helmerhorst F.M.
        Oral contraceptives containing drospirenone for premenstrual syndrome.
        Cochrane Database Syst Rev. 2009; ([Art. No.: CD006586])https://doi.org/10.1002/14651858.CD006586.pub3
        • Breech L.L.
        • Braverman P.K.
        Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder.
        Int J Women's Health. 2010; 1: 85-95